SV et al. sell Convergence for $675m
SV Life Sciences, New Leaf Venture Partners and Apposite Capital have sold UK-based biotechnology company Convergence Pharmaceuticals to Nasdaq-listed Biogen Idec for a total consideration of $675m.
More on Exits
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Actera Group explores strategic options for Celebi Ground Handling
Several investors placed bids for the company in 2022 but mismatch in pricing didn't lead to a deal
Norstat owner Triton Partners explores sale via William Blair
GP has owned the Norway-headquarterd market research business for almost four years
IK Investment-backed Eres expected to hit the auction block by 2024
French employee savings distribution and management firm could be valued at a few hundred million euros
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds